Notice · For research and educational reference. Not medical advice. Intended for licensed professionals. Nothing on this site is offered for sale other than informational access.

All Info Peptides
All monographs

Growth Hormone Secretagogues

Tesamorelin

Overview

An N-terminally modified GHRH analogue investigated in HIV-associated lipodystrophy research. The hexenoyl modification confers resistance to dipeptidyl-peptidase IV degradation.

Research profile · for clinicians

Based on research: best characterized in the visceral-fat and metabolic literature. Elevates the body's own GH and downstream IGF-1, which in HIV-associated lipodystrophy trials tracked with meaningful visceral adipose tissue reduction; also explored in fatty-liver cohorts.

Mechanism of action

Stimulates endogenous GH release via GHRH receptor agonism; downstream IGF-1 elevation has been associated with visceral adipose tissue reduction in study cohorts.

Research record

  • [01]Reduction of visceral adipose tissue in HIV-lipodystrophy trials.
  • [02]Investigations in non-alcoholic fatty liver disease cohorts.

Selected references

  • Effects of tesamorelin on VAT

    JAMA, 2007